"Dartmouth Cancer Center is one of the nation's premier facilities for cancer treatment and research. It is one of only 51 National Cancer Institute-designated comprehensive cancer centers in the United States. The Cancer Center provides a positive environment for treatment, cure, and recovery for patients with all forms of cancer. Patients receive technologically advanced cancer treatments and access to clinical trials of new treatments. Each patient is seen as an individual, and a specific treatment plan is developed by specialists who work directly with the patient, family, and referring physician. The Cancer Center is also a leader in improving the comfort and quality of life of patients."

During the past decade, Norris Cotton Cancer Center-Manchester conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 35 clinical trials were completed, i.e. on average, 97.2% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 25 clinical trials were completed. i.e. 1250% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Norris Cotton Cancer Center-Manchester" #1 sponsor was "National Cancer Institute (NCI)" with 29 trials, followed by "SWOG Cancer Research Network" with 16 trials sponsored, "Alliance for Clinical Trials in Oncology" with 6 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 2 trials sponsored and "Gynecologic Oncology Group" with 2 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Norris Cotton Cancer Center-Manchester" #1 collaborator was "National Cancer Institute (NCI)" with 26 trials as a collaborator, "NRG Oncology" with 5 trials as a collaborator, "Canadian Cancer Trials Group" with 2 trials as a collaborator, "Eastern Cooperative Oncology Group" with 2 trials as a collaborator and "Astellas Pharma US, Inc." with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Norris Cotton Cancer Center-Manchester" are "Recurrent Squamous Cell Lung Carcinoma" (8 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (7 trials), "Recurrent Breast Carcinoma" (6 trials), "Stage IIIA Breast Cancer AJCC v7" (5 trials) and "Stage IIIC Breast Cancer AJCC v7" (4 trials). Many other conditions were trialed in "Norris Cotton Cancer Center-Manchester" in a lesser frequency.

Most popular intervention types in "Norris Cotton Cancer Center-Manchester" are "Drug" (45 trials), "Other" (42 trials), "Biological" (27 trials), "Procedure" (8 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (29 trials), "Quality-of-Life Assessment" (14 trials), "Paclitaxel" (8 trials), "Bevacizumab" (7 trials) and "Docetaxel" (7 trials). Other intervention names were less common.

The vast majority of trials in "Norris Cotton Cancer Center-Manchester" are 45 trials for "All" genders, 9 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Norris Cotton Cancer Center-Manchester". undefined are not yet recruiting, 5 are recruiting, 31 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Norris Cotton Cancer Center-Manchester, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Norris Cotton Cancer Center-Manchester, 2 "Phase 1" clinical trials were conducted, 26 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".